Skip to main content
OpenTrials
Completed

NCT Number: NCT05372224

Effect of Vitamin D and Denosumab on Bone Remodelling in Women With Postmenopausal Osteoporosis

Denosumab is a monoclonal antibody against RANKL ligand, which is used as an alternative treatment for osteoporosis in patients who have a poor response to first-line antiresorptive therapy. However, discontinuation of denosumab produces a rapid increase in bone turnover, bone loss and potentially increased risk of multiple vertebral fractures.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year–89 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Patricia Loranca-Moreno

Mexico City, Gustavo A. Madero, 07300, Mexico

About this study

76 postmenopausal women from the climacteric clinic of the regional hospital "1o de Octubre" of the Institute of Security and Social Services for State Workers (ISSSTE) were firstly considered, of which 23 presented elimination criteria and only 55 who had received denosumab therapy for an average of 2.5 years without a significant improvement in hip and lumbar spine T-scores were enrolled. First, a general medical evaluation was performed. Serum levels of vitamin D were analysed to find the prevalence of hypovitaminosis D. A bone mineral density test was done to calculate hip and lumbar spine T-scores. Then, vitamin D was administrated daily for one year at a dose of 4,000 IU and the studies were repeated after one year. Statistical analysis was performed using PAST 3.0 and GraphPad Prism 8.4.3. software. The arithmetic median (µ) and standard deviation (S.D.) were calculated using Excel-Word. Graphics were constructed with GraphPad Prism 8.4.3 and tables with Excel Word. Categorical variables were analysed with chi-squared or Fisher exact test depending on the number of participants in each cell. Normality was determined using the Shapiro-Wilk test. To compare two paired samples, the Wilcoxon signed-rank test was utilized. The assigned α value for this study was <0.05. In all cases, if a Montecarlo permutation was available, the exact p-value was taken instead of the raw p-value.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of postmenopausal osteoporosis or osteopenia in treatment with denosumab 60mg every six months plus calcium carbonate 1.2g/day + vitamin D 800IU/day.
  • Diagnosis of hypovitaminosis D, with serum cholecalciferol values <30ng/dL.

Exclusion criteria

  • Incomplete clinical records or clinical records.
  • Age over 90 years.
  • Diagnosis of secondary (hereditary) osteoporosis.
  • History of prolonged use of steroids.
  • Lack of adherence to medical treatment.
  • Diagnosis of cancer.
  • Diagnosis of depression.
  • Diagnosis of Celiac disease or with the presence of alterations in intestinal absorption.
  • Allergies to any of the medications administered.

Treatment and study plan

Cholecalciferol

Drug

4000 IU were administrated once a day for 3 months.

Other names: Histofil®

Primary outcomes

  1. Number of participants with hip T-score improvement at 12 months

    Time frame: 12 months

    It refers to the number of participants who improved their hip T-score at three months after treatment.

  2. Number of participants with lumbar spine T-score improvement at 12 months

    Time frame: 12 months

    It refers to the number of participants who improved their lumbar spine T-score at three months after treatment.

  3. Number of participants with osteoporosis of the hip at 12 months

    Time frame: 12 months

    It refers to the number of participants that present a hip T-score above -2.5 three months after treatment.

  4. Number of participants with osteoporosis of the lumbar spine at 12 months

    Time frame: 12 months

    It refers to the number of participants that present a lumbar spine T-score greater than -2.5 three months after treatment.

  5. Number of participants with osteopenia on the hip at 12 months

    Time frame: 12 months

    It refers to the number of participants that present a hip T-score from -1 to -2.4 three months after treatment.

  6. Number of participants with osteopenia of the lumbar spine at 12 months

    Time frame: 12 months

    It refers to the number of participants that present a lumbar spine T-score from -1 to -2.4 three months after treatment.

  7. Number of participants with normal hip T-score at 12 months

    Time frame: 12 months

    It refers to the number of participants that present a hip T-score below -1 three months after treatment.

  8. Number of participants with normal lumbar spine T-score at 12 months

    Time frame: 12 months

    It refers to the number of participants that present a lumbar spine T-score below -1 three months after treatment.

  9. Number of participants with improvement in serum levels of vitamin D at 12 months

    Time frame: 12 months

    Improvement in serum levels of 25-hydroxy vitamin D [25(OH)D] was considered when serum vitamin D levels increased concerning baseline levels.

  10. Number of participants with clinical remission of hypovitaminosis D at 12 months

    Time frame: 12 months

    Remission of hypovitaminosis D was considered when serum levels of 25-hydroxy vitamin D [25(OH)D] were above 29 pg/ml.

Secondary outcomes

  1. Number of participants with vitamin D sufficiency at 12 months

    Time frame: 12 months

    It refers to the number of participants who reached serum levels of vitamin D above 29 pg/ml after three months of treatment.

  2. Number of participants with vitamin D insufficiency at 12 months

    Time frame: 12 months

    It refers to the number of participants who reached serum levels of vitamin D of 21 to 29 pg/ml after three months of treatment.

  3. Number of participants with vitamin D deficiency at 12 months

    Time frame: 12 months

    It refers to the number of participants who reached serum levels of vitamin D less than 20 pg/ml after three months of treatment.

Sponsors and collaborators

Lead sponsor

Hospital Regional 1o de Octubre

Other

Collaborators

  • National Polytechnic Institute, Mexico
  • Universidad Nacional Autonoma de Mexico

Registry information

Official study title

Vitamin D Improves Osteoporosis in Postmenopausal Women With Denosumab Failure

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
May 12, 2022
Registry last updated
Feb 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.